| Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery (NCT07311369) | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | 2025-12-01 |
| Prevention of Cisplatin-induced Nephrotoxicity (NCT06196853) | Mahidol University | 2025-12-01 |
| WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC (NCT07330050) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-01 |
| Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy (NCT06570915) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 |
| A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients (NCT07267208) | Jongman Kim | 2025-12-01 |
| A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer (NCT07269158) | Yonsei University | 2025-12-01 |
| Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors (NCT07258160) | Second Affiliated Hospital of Soochow University | 2025-12-01 |
| A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread (NCT07256223) | Fudan University | 2025-12-01 |
| TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy (NCT07330037) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-01 |
| Adjuvant Chemotherapy for BTC Based on 3D-PTA (NCT07296666) | Fudan University | 2025-12-01 |
| Effect of Colchicine in Patients With Myocardial Infarction (NCT04218786) | Shifa Tameer-e-Millat University | 2025-12-01 |
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder (NCT06561009) | Tianjin Medical University General Hospital | 2025-12-01 |
| The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab. (NCT07212062) | Neurology Office of South Florida | 2025-12-01 |
| Assessment of Corneal Endothelial Function Following Hypoxic Stress (NCT04175938) | Massachusetts Eye and Ear Infirmary | 2025-12-01 |
| Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine (NCT07168018) | University of Oxford | 2025-12-01 |
| Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer (NCT07305246) | First Hospital of China Medical University | 2025-12-01 |
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. (NCT07227012) | Pfizer | 2025-12-01 |
| A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer (NCT07347951) | First Affiliated Hospital of Wenzhou Medical University | 2025-12-01 |
| A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis (NCT07232576) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2025-12-01 |
| Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections (NCT07224997) | Hospital Civil de Guadalajara | 2025-12-01 |
| Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis (NCT05107934) | R-Pharm Overseas, Inc. | 2025-12-01 |
| Prevent Cognitive Decline in GBA-associated Parkinson's Disease (NCT07055087) | University Hospital Tuebingen | 2025-12-01 |
| Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial (NCT07261709) | Sun Yat-sen University | 2025-12-01 |
| Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate (NCT07230509) | Minia University | 2025-12-01 |
| Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population (NCT06559215) | Texas Scottish Rite Hospital for Children | 2025-12-01 |
| A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER (NCT07101822) | Hospital Israelita Albert Einstein | 2025-12-01 |
| A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer (NCT07644286) | Tao Zhang | 2025-12-01 |
| Resuscitation Enhancement to Avoid Rearrest Through Evidence-based Strategies in Prehospital Post-resuscitation Care (NCT07239908) | Siriraj Hospital | 2025-12-01 |
| Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment (NCT07201675) | Qilu Hospital of Shandong University | 2025-12-01 |
| Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (NCT07530094) | Ning Jiang, M.D./Ph.D. | 2025-12-01 |
| Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome (NCT07312864) | Beijing Friendship Hospital | 2025-12-01 |
| Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis (NCT05105958) | University of Zurich | 2025-12-01 |
| A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. (NCT07200947) | Zhijie Wang | 2025-12-01 |
| Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease (NCT06682234) | Gilead Sciences | 2025-12-01 |
| Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC (NCT07235306) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-12-01 |
| Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression (NCT07183748) | Beersheva Mental Health Center | 2025-12-01 |
| Linaclotide for Colonoscopy Bowel Prep (NCT06692673) | University of Florida | 2025-12-01 |
| The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation (NCT07247734) | Asger Lund, MD | 2025-12-01 |
| Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer (NCT07254858) | First Affiliated Hospital of Wenzhou Medical University | 2025-12-01 |
| A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus (NCT06789302) | Global Institute of Stem Cell Therapy and Research | 2025-12-01 |
| Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis (NCT07122648) | Paean Biotechnology Inc. | 2025-12-01 |
| Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial (NCT07260825) | TriHealth Inc. | 2025-12-01 |
| Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE) (NCT07434271) | Kadence Bio | 2025-12-01 |
| Sarcoma Surgery Wound Complications Comparing Usual Versus Negative Pressure Dressing (NCT07048184) | NHS Greater Glasgow and Clyde | 2025-12-01 |
| A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma (NCT07239986) | Broadenbio Ltd., Co. | 2025-12-01 |
| Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer (NCT07244926) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-01 |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan (NCT07196644) | AbbVie | 2025-12-01 |
| Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC (NCT07244874) | Tianjin Medical University Cancer Institute and Hospital | 2025-12-01 |
| Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer (NCT07392346) | Dai, Guanghai | 2025-12-01 |
| Clostridium Butyricum in Stenosing Crohn's Desease (NCT07263880) | San Giovanni Addolorata Hospital | 2025-12-01 |
| Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (NCT07435454) | Jiangsu Cancer Institute & Hospital | 2025-12-01 |
| Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia (NCT06547866) | French Innovative Leukemia Organisation | 2025-12-01 |
| Clinical Efficacy and Safety of MB LuxuryⓇ Product Containing Epigallocathecin Gallate (EGCG) on Erythema, Melanin, and Skin Hydration (NCT07725900) | Naniek Widyaningrum | 2025-12-01 |
| "Efesovir" (FS-1) for COVID-19, Phase 2 (NCT05060705) | Scientific Center for Anti-infectious Drugs, Kazakhstan | 2025-12-01 |
| A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin (NCT04662164) | Shanghai HEP Pharmaceutical Co., Ltd. | 2025-12-01 |
| Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke (NCT05367362) | State University of New York at Buffalo | 2025-12-01 |
| Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression (NCT07670026) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-12-01 |
| Study of CHO-A04 in Advanced Solid Tumors (NCT07049458) | Cho Pharma Inc. | 2025-12-01 |
| Nebulized Nasal Steroids (NCT07270302) | Washington University School of Medicine | 2025-12-01 |
| Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study (NCT07264010) | Nanfang Hospital, Southern Medical University | 2025-12-01 |
| Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors (NCT03393962) | Shenzhen Geno-Immune Medical Institute | 2025-12-01 |
| Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia (NCT07278908) | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 |
| MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER (NCT07458022) | University of Child Health Sciences and Children's Hospital, Lahore | 2025-12-01 |
| the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients (NCT07692256) | Ain Shams University | 2025-12-01 |
| A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma (NCT07250594) | Advagene Biopharma Co. Ltd. | 2025-12-01 |
| Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer (NCT07244965) | Women's Hospital School Of Medicine Zhejiang University | 2025-12-01 |
| A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) (NCT07264595) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-12-01 |
| An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia (NCT06281847) | Advesya SAS | 2025-12-01 |
| Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy (NCT06958705) | The First Affiliated Hospital with Nanjing Medical University | 2025-12-01 |
| A Phase 2 Study of CRD-4730 in CPVT (NCT06658899) | Cardurion Pharmaceuticals, Inc. | 2025-12-01 |
| A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment (NCT07229872) | Harbin Medical University | 2025-12-01 |
| Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome (NCT03304717) | Children's Hospital of Philadelphia | 2025-12-01 |
| Photobiomodulation for the Prevention of Oral Mucositis (NCT07290413) | Brigham and Women's Hospital | 2025-12-01 |
| Levosimendan in Acute Decompensated Heart Failure (NCT07262723) | Chittagong Medical College | 2025-12-01 |
| Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer (NCT07261683) | Obstetrics & Gynecology Hospital of Fudan University | 2025-12-01 |
| Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT06134414) | Wuhan Createrna Science and Technology Co., Ltd | 2025-12-01 |
| Nu-3 Gel for Infected Diabetic Foot Ulcers (NCT06020235) | Lakewood-Amedex Inc | 2025-12-01 |
| Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites (NCT05375708) | UMC Utrecht | 2025-12-01 |
| Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib (NCT07230314) | Jinling Hospital, China | 2025-11-30 |
| A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer (NCT07256509) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-11-30 |
| Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma (NCT07236528) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2025-11-30 |
| Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study (NCT07243418) | Fujian Cancer Hospital | 2025-11-30 |
| A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma (NCT07252375) | Fujian Cancer Hospital | 2025-11-30 |
| Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (NCT07241819) | Peking University Cancer Hospital & Institute | 2025-11-30 |
| A Multicenter Study of CAR-T Cells in Primary Ph+All (NCT07252336) | Zhejiang University | 2025-11-30 |
| Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions (NCT07230301) | Sizhen Wang | 2025-11-30 |
| Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL (NCT07255963) | The First Affiliated Hospital of Soochow University | 2025-11-30 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. (NCT05770544) | Cancer Research UK | 2025-11-30 |
| A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer (NCT07143292) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2025-11-30 |
| CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer (NCT07268794) | Fudan University | 2025-11-30 |
| Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer (NCT06177522) | Jinling Hospital, China | 2025-11-30 |
| SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma (NCT07274774) | Shandong Cancer Hospital and Institute | 2025-11-30 |
| A Phase Ⅱa Clinical Study of CL-197 Capsules (NCT07308782) | Henan Genuine Biotech Co., Ltd. | 2025-11-29 |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) (NCT07296484) | Sparrow Pharmaceuticals | 2025-11-29 |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma (NCT07259070) | Institute of Hematology & Blood Diseases Hospital, China | 2025-11-29 |
| Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. (NCT07244380) | Hebei Senlang Biotechnology Inc., Ltd. | 2025-11-28 |
| Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma (NCT07243951) | Shanghai Zhongshan Hospital | 2025-11-28 |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer (NCT07169851) | Eli Lilly and Company | 2025-11-28 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma (NCT07288203) | Iovance Biotherapeutics, Inc. | 2025-11-28 |
| Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction (NCT06974526) | Science Valley Research Institute | 2025-11-28 |